Provectus Biopharmaceuticals (PVCT) 10-K 5 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 02, 2020	Jun. 28, 2019
Document And Entity Information
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 23,304,507
Entity Common Stock, Shares Outstanding		390,689,475
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 590,706	$ 50,986
Short-term receivables - legal fees, settlement and other, net	55,058	595,326
Prepaid expenses	350,249	370,209
Total Current Assets	996,013	1,016,521
Equipment and furnishings, less accumulated depreciation of $64,630 and $50,538, respectively	58,384	72,476
Operating lease right-of-use asset	194,400
Patents, net of accumulated amortization of $11,487,338 and $10,816,218, respectively	228,107	899,227
Total Assets	1,476,904	1,988,224
Current Liabilities:
Accounts payable - trade	1,125,890	3,312,049
Accrued interest	65,333
Convertible notes payable	500,000
Other accrued expenses	1,255,266	790,358
Current portion of operating lease liability	76,423
Total Current Liabilities	3,022,912	4,102,407
Accrued interest	1,501,864	659,379
Accrued interest - related parties	1,226,582	711,927
Convertible notes payable	12,997,000	7,062,000
Convertible notes payable - related parties	6,670,000	6,870,000
Non-current portion of operating lease liability	130,658
Total Liabilities	25,549,016	19,405,713
Commitments and contingencies (Note 10)
Stockholders' Deficiency:
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at December 31, 2019 and December 31, 2018; aggregate liquidation preference of $3,500 at December 31, 2019 and December 31, 2018
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 389,889,475 and 384,614,528 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively	389,889	384,615
Additional paid-in capital	209,378,835	209,092,187
Accumulated other comprehensive loss	(24,008)
Accumulated deficit	(233,816,828)	(226,894,291)
Total Stockholders' Deficiency	(24,072,112)	(17,417,489)
Total Liabilities and Stockholders' Deficiency	$ 1,476,904	$ 1,988,224

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accumulated depreciation on equipment and furnishings	$ 64,630	$ 50,538
Accumulated amortization on patents	$ 11,487,338	$ 10,816,218
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Aggregate liquidation preference	$ 3,500	$ 3,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	389,889,475	384,614,528
Common stock, shares outstanding	389,889,475	384,614,528
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Expenses:
Research and development	$ 4,002,014	$ 4,747,557
General and administrative	2,297,682	3,306,668
Total Operating Expenses	6,299,696	8,054,225
Total Operating Loss	(6,299,696)	(8,054,225)
Other Income/(Expense):
Gain on settlement of lawsuits	675,000	825,000
Research and development tax credit	134,081	26,325
Investment and interest income	23,162	19,560
Interest expense	(1,455,084)	(969,715)
Net Loss	$ (6,922,537)	$ (8,153,055)
Basic and Diluted Loss Per Common Share	$ (0.02)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	386,593,634	382,338,471

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Net Loss	$ (6,922,537)	$ (8,153,055)
Other Comprehensive Loss:
Foreign currency translation adjustments	(24,008)
Total Comprehensive Loss	$ (6,946,545)	$ (8,153,055)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficiency - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Preferred Stock Series B [Member]
Beginning Balance
Beginning Balance, shares	100	100
Common stock issued upon exercise of warrants
Common stock issued upon exercise of warrants, shares
Common stock issued in lieu of accounts payable
Common stock issued in lieu of accounts payable, shares
Common stock issued for services
Common stock issued for services, shares
Warrants issued for services
Net loss
Other comprehensive loss
Ending Balance
Ending Balance, shares	100	100
Common Stock [Member]
Beginning Balance	$ 384,615	$ 370,962
Beginning Balance, shares	384,614,528	370,961,451
Common stock issued upon exercise of warrants	$ 5,045	$ 12,653
Common stock issued upon exercise of warrants, shares	5,045,857	12,653,077
Common stock issued in lieu of accounts payable		$ 1,000
Common stock issued in lieu of accounts payable, shares		1,000,000
Common stock issued for services	$ 229
Common stock issued for services, shares	229,090
Warrants issued for services
Net loss
Other comprehensive loss
Ending Balance	$ 389,889	$ 384,615
Ending Balance, shares	389,889,475	384,614,528
Additional Paid-In Capital [Member]
Beginning Balance	$ 209,092,187	$ 208,351,431
Common stock issued upon exercise of warrants	263,898	661,756
Common stock issued in lieu of accounts payable		79,000
Common stock issued for services	11,309
Warrants issued for services	11,441
Net loss
Other comprehensive loss
Ending Balance	209,378,835	209,092,187
Accumulated Other Comprehensive Loss [Member]
Beginning Balance
Common stock issued upon exercise of warrants
Common stock issued in lieu of accounts payable
Common stock issued for services
Warrants issued for services
Net loss
Other comprehensive loss	(24,008)
Ending Balance	(24,008)
Accumulated Deficit [Member]
Beginning Balance	(226,894,291)	(218,741,236)
Common stock issued upon exercise of warrants
Common stock issued in lieu of accounts payable
Common stock issued for services
Warrants issued for services
Net loss	(6,922,537)	(8,153,055)
Other comprehensive loss
Ending Balance	(233,816,828)	(226,894,291)
Beginning Balance	(17,417,489)	(10,018,843)
Common stock issued upon exercise of warrants	268,943	674,409
Common stock issued in lieu of accounts payable		80,000
Common stock issued for services	11,538
Warrants issued for services	11,441
Net loss	(6,922,537)	(8,153,055)
Other comprehensive loss	(24,008)
Ending Balance	$ (24,072,112)	$ (17,417,489)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities:
Net loss	$ (6,922,537)	$ (8,153,055)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	22,979	80,000
Noncash lease expense	71,150
Depreciation	14,092	14,093
Amortization of patents	671,120	671,120
Changes in operating assets and liabilities
Settlement receivable	4,907	528,235
Prepaid expenses	19,960	30,207
Accounts payable - trade	(2,186,159)	41,544
Other accrued expenses	731,134	613,215
Operating lease liability	(71,945)
Accrued interest expense	1,455,084	969,715
Net Cash Used In Operating Activities	(6,190,215)	(5,204,926)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	6,435,000	2,606,000
Proceeds from issuance of convertible notes payable - related parties	50,000	1,870,000
Proceeds from exercise of warrants	268,943	674,408
Net Cash Provided By Financing Activities	6,753,943	5,150,408
Effect of Exchange Rate Changes on Cash	(24,008)
Net Increase (Decrease) In Cash and Cash Equivalents	539,720	(54,518)
Cash and Cash Equivalents, Beginning of Year	50,986	105,504
Cash and Cash Equivalents, End of Year	590,706	50,986
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Offset of related party receivable against note payable, accrued interest, and accrued expenses	$ 535,361	$ 150,000

Business Organization and Natur

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	1. Business Organization and Nature of Operations Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company that is developing a new class of drugs for oncology, hematology, and dermatology based on an entire, wholly-owned, family of small molecules called halogenated xanthenes: ● Oncology: PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma). Orphan drug designation status has been granted to PV-10 by the FDA for neuroblastoma in 2018. ● Hematology. ● Dermatology: To date, the Company has not generated any revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash and cash equivalents were $590,706 at December 31, 2019, compared with $50,986 at December 31, 2018. The Company continues to incur significant operating losses and management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10 and PH-10 and raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, including the 2020 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2020 Financing or otherwise, it will not be able to pay its obligations as they become due. Subsequent to December 31, 2019, the Company received an aggregate $50,000 in connection with the 2020 Financing. In addition, holders of 800,000 warrants to purchase the common stock of the Company at $0.0533 per share, have exercised these warrants. As a result, the Company has received aggregate proceeds in the amount of $42,640. See Note 13 – Subsequent Events. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company, or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2020 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2020 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the collectability of receivables, the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2019, and 2018, the Company’s cash equivalent consists of Treasury bills. Cash Concentrations Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers, leasehold improvements and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2019 and 2018. Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are being amortized over the remaining estimated useful lives of the patents, which is approximately one year. Annual amortization of the patents is expected to approximate $228,000 in 2020. Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 6 - Receivables. Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. The adoption of ASC 842 had a material impact on the Company’s consolidated balance sheet but did not have a material impact on the Company’s consolidated statement of operations. The impact of the adoption of ASC Topic 842 on the balance sheet as of January 1, 2019 is as follows: As Reported December 31, 2018 Adoption of ASC 842 Balance January 1, 2019 Operating lease right-of-use asset $ - $ 265,550 $ 265,550 Total assets $ 1,988,224 $ 265,550 $ 2,253,774 Current liabilities $ 4,102,407 $ 58,469 $ 4,160,876 Non-current portion of operating lease liability $ - $ 207,081 $ 207,081 Total liabilities $ 19,405,713 $ 265,550 $ 19,671,263 Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2019 or 2018. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2019 2018 Warrants 126,109,532 136,824,138 Options 3,000,000 3,200,000 Convertible preferred stock 65,663 65,663 Total potentially dilutive shares 129,175,195 140,089,801 The potential dilutive effect of the conversion of the Company’s convertible notes payable has been excluded from this table since the Company’s Series D Preferred Stock has yet to be designated by the Board. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2019 and 2018. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, receivables, other current assets, accounts payable, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability. In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($61,380 and $308,915 at December 31, 2019 and $15,049 and $336,031 at December 31, 2018, respectively), and expense accounts are translated at a weighted average exchange rate for the years then ended ($53,210 and $247,947 for the years ended December 31, 2019 and 2018, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive income (“AOCI”), which is a separate component of shareholders’ equity. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denomination transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning December 1, 2019 and subsequent interim periods. The Company is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments —Credit Losses, ASU 2019-05, Financial Instruments —Credit Losses (Topic 326) Targeted Transition Relief, ASU 2016-13, the FASB issued ASU 2019-10 Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) and ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments—Credit Losses. These ASUs do not change the core principle of the guidance in ASU 2016-13. Instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard. These ASUs will have the same effective date and transition requirements as ASU 2016-13. The Company adopted ASU 2016-13 on January 1, 2020 and it did not have a material impact on the consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted ASU effective January 1, 2020 and it did not have a material impact on the consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied on a prospective basis. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	4. Convertible Notes Payable 2017 Financing On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company’s stockholders (the “PRH Group”), which was amended and restated effective as of March 19, 2017 (the 2017 Term Sheet) that set forth the terms on which the PRH Group would use their best efforts to arrange for a financing of a minimum of $10,000,000 and maximum of $20,000,000 (the “2017 Financing”). The 2017 Financing was in the form of a secured convertible loan (the “1 st st (i) It is secured by a first priority security interest on the Company’s IP, (ii) The 1 st (iii) The 1 st (iv) The 2017 Notes, including interest and principal, are due and payable in full on the earlier of: (i) on such date upon which the Company defaults under the 2017 Notes, (ii) upon a change of control of the Company, or (iii) dates ranging from May 18, 2020 to the 18-month anniversary of the funding of the Final Tranche. In the event there is a change of control of the Company’s Board as proposed by any person or group other than the Investors, the term of the 2017 Notes will be accelerated and all amounts due under the 2017 Notes will be immediately due and payable, plus interest at the rate of 8% per annum, plus a penalty in the amount equal to 10 times the outstanding principal amount of the 1 st (v) The outstanding principal amount and interest payable under the 1 st st (vi) Notwithstanding (v) above, the principal amount of the 2017 Notes and the interest payable under the 1 st Pursuant to the 2017 Term Sheet, the PRH Group concluded its best efforts activity to arrange for a financing of $20,000,000, which amounts were provided in a number of tranches, between the first tranche on April 4, 2017 and the Final Tranche on December 20, 2019. As a result, the 2017 Notes under the 1 st Upon conversion of the 2017 Notes, the 1 st 2020 Financing On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $20,000,000 (the “2020 Financing”). As of December 31, 2019, the Company had received aggregate 2 nd The 2020 Term Sheet is similar to the 2017 Term Sheet. Subject to the terms and conditions of the 2020 Term Sheet, the Company will use its best efforts to arrange for the 2020 Financing, which amounts will be obtained in several tranches. The proceeds from the 2020 Financing will be used to fund the Company’s clinical development program, as currently constituted and envisioned, and to fund the Company’s general and administrative expenses. The 2020 Financing will be in the form of a secured convertible loan (the “2 nd nd (i) It will be secured by a second priority security interest on the Company’s IP subordinate to the first priority security interest of the 2017 Notes; (ii) The 2 nd (iii) In the event there is a change of control of the Company’s Board, the term of the 2020 Notes will be accelerated and all amounts due under the 2020 Notes will be immediately due and payable, plus interest at the rate of eight percent (8%) per annum, plus a penalty in the amount equal to ten times (10x) the outstanding principal amount of the 2 nd (iv) The outstanding principal amount and interest payable under the 2 nd nd (v) Notwithstanding (iv) above, the principal amount of the 2020 Notes and the interest payable under the 2 nd The Series D Preferred Stock The Series D Preferred Stock shall have a first priority right to receive proceeds from the sale, liquidation or dissolution of the Company or any of the Company’s assets (each, a “Company Event”). If a Company Event occurs within two (2) years of the date of issuance of the Series D Preferred Stock (the “Date of Issuance”), the holders of Series D Preferred Stock shall receive a preference of four times (4x) their respective investment amount. If a Company Event occurs after the second (2nd) anniversary of the Date of Issuance, the holders of the Series D Preferred Stock shall receive a preference of six times (6x) their respective investment amount. The Series D Preferred Stock will become convertible at the option of the holders thereof into shares of the Company’s common stock based on a formula to achieve a one-for-ten conversion ratio. The Series D Preferred Stock shall automatically convert into shares of the Company’s common stock upon the fifth (5 th On an as-converted basis, the Series D Preferred Stock shall carry the right to ten (10) votes per share. The Series D Preferred Stock shall not have any dividend preference but shall be entitled to receive, on a pari passu As of December 31, 2019, and through the date of filing, the Series D Preferred Stock had not been designated by the Board. Per the terms of the 2017 Notes and 2020 Notes, if the Company has not designated the Series D Preferred Stock or if an insufficient number of Series D Preferred shares exist upon a conversion by a note holder, then the outstanding loans will continue to accrue interest at a rate of 8% per annum until which time the Company has designated a sufficient number of Series D Preferred shares. As a result, the Company did not analyze the 2 nd nd nd nd pari passu st Convertible Notes Payable – Related Parties During the year ended December 31, 2018, the Company entered into 2017 Notes with related parties in the aggregate principal amount of $1,870,000. As of December 31, 2018, the Company had borrowed $6,870,000 of 2017 Notes from related parties which were outstanding. During the year ended December 31, 2019, the Company entered into 2017 Notes with related parties in the aggregate principal amount of $50,000 offset by the application of the 2017 Note in the principal amount of $250,000 that the Company entered into with Timothy Scott and Leigh Anne Scott on February 28, 2018 that was applied to Dr. Scott’s Kleba Settlement agreement. As of December 31, 2019, the Company had borrowed $6,670,000 of 2017 Notes from related parties which were outstanding. Convertible Notes Payable – Non-Related Parties During the year ended December 31, 2018, the Company entered into 2017 Notes with accredited investors in the aggregate principal amount of $2,606,000. As of December 31, 2018, the Company had borrowed $7,062,000 under these notes, all of which were outstanding as of that date. During the year ended December 31, 2019, the Company entered into 2017 Notes with accredited investors in the aggregate principal amount of $6,335,000. As of December 31, 2019, the Company had borrowed $13,397,000 under these notes, all of which were outstanding as of that date. During the year ended December 31, 2019, the Company entered into a 2020 Note with an accredited investor in the principal amount of $100,000. As of December 31, 2019, the Company had borrowed $100,000 under this note.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions During the years ended December 31, 2019 and 2018, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $277,200 and $190,000, respectively, for services rendered. Accrued director fees for Mr. Horowitz as of December 31, 2019 and 2018 were $75,000 and $56,250, respectively. Mr. Horowitz serves as both COO and a Director. See Note 4 and Note 6 for details of other related party transactions. Director fees during the years ended December 31, 2019 and 2018 were $385,000 and $333,357, respectively. Accrued directors’ fees as of December 31, 2019 and 2018 were $792,524 and $407,524, respectively.

Receivables

Receivables	12 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Receivables	6. Receivables The following table summarizes the receivables at December 31, 2019 and 2018: December 31, 2019 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 55,058 $ 55,058 Gross receivable $ 455,500 $ 1,649,043 $ 2,104,543 Reserve for uncollectibility (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 55,058 - - 55,058 Short-term receivable - Tax Credit 55,058 - - 55,058 Short-term receivable - Settlement - - - Short-term receivable - Legal - - - Long-term receivable $ - $ - $ - $ - December 31, 2018 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 5,074 $ 5,074 Gross receivable $ 911,000 $ 1,783,795 $ 2,694,795 Reserve for uncollectibility (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable 455,500 134,752 595,326 Short-term receivable - Tax Credit Short-term receivable - Settlement - 134,752 134,752 Short-term receivable - Legal 455,500 - 455,500 Long-term receivable $ - $ - $ - $ - During the year ended December 31, 2018, an officer of the Company offset his settlement amounts owed to the Company against accrued payroll owed to him totaling $150,000. This offset reduced the amount of the settlement and was approved by the Company’s Board. During the year ended December 31, 2019, officers of the Company offset their settlement amounts owed to the Company against accrued payroll and other payables totaling $535,361. This offset reduced the amount of the settlement and was approved by the Company’s Board. See Note 12 - Litigation for additional details.

Stockholders' Deficiency

Stockholders' Deficiency	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Deficiency	7. Stockholders’ Deficiency Authorized Capital As of December 31, 2019, the Company was authorized to issue 1,000,000,000 shares of common stock, $0.001 par value, and 25,000,000 shares of preferred stock, $0.001 par value. The holders of the Company’s common stock are entitled to one vote per share. The preferred stock is designated as follows: 240,000 shares to Series B Convertible Preferred Stock (the “Series B Preferred Stock”) and 24,760,000 shares undesignated. Series B Convertible Preferred Stock On August 25, 2016, the Company filed the Series B Certificate of Designation with the Delaware Secretary of State. The Series B Certificate of Designation provides for the issuance of the Series B Preferred Stock, par value $0.001 per share. In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Preferred Stock will be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Series B Preferred Stock if such shares had been converted to common stock immediately prior to such event (without giving effect for such purposes to any beneficial ownership limitation), subject to the preferential rights of holders of any class or series of the Company’s capital stock specifically ranking by its terms senior to the Series B Preferred Stock as to distributions of assets upon such event, whether voluntarily or involuntarily. The Series B Preferred Stock has no voting rights. The holders of Series B Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 8% per annum of the stated value per share, until the fifth anniversary of the date of issuance of the Series B Preferred Stock. The dividends become payable, at the Company’s option in either cash, out of any funds legally available for such purpose, or in shares of common stock, (i) upon any conversion of the Series B Preferred Stock, (ii) on each such other date as the Board may determine, subject to written consent of the holders of Series B Preferred Stock holding a majority of the then issued and outstanding Series B Preferred Stock, (iii) upon the Company’s liquidation, dissolution or winding up, and (iv) upon occurrence of a fundamental transaction, which includes any merger or consolidation, sale of all or substantially all of the Company’s assets, exchange or conversion of all of the common stock by tender offer, exchange offer or reclassification; provided, however, that if Series B Preferred Stock is converted into shares of common stock at any time prior to the fifth anniversary of the date of issuance of the Series B Preferred Stock, the holder will receive a make-whole payment in an amount equal to all of the dividends that, but for the early conversion, would have otherwise accrued on the applicable shares of Series B Preferred Stock being converted for the period commencing on the conversion date and ending on the fifth anniversary of the date of issuance, less the amount of all prior dividends paid on such converted Series B Preferred Stock before the date of conversion. Make-whole payments are payable at the Company’s option in either cash, out of any funds legally available for such purpose, or in shares of common stock. With respect to any dividend payments and make-whole payments paid in shares of common stock, the number of shares of common stock to be issued to a holder of Series B Preferred Stock will be an amount equal to the quotient of (a) the amount of the dividend payable to such holder divided by (b) the conversion price then in effect. Other Common Stock Issuances During the year ended December 31, 2018, the Company issued 1,000,000 shares of immediately vested restricted common stock as payment of services, with an issuance date fair value of $80,000, which was recognized immediately. During the year ended December 31, 2019, the Company issued 229,090 shares of immediately vested restricted common stock with an issuance date value of $11,538, which was recognized immediately.

Stock Incentive Plan and Warran

Stock Incentive Plan and Warrants	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Incentive Plan and Warrants	8. Stock Incentive Plan and Warrants The Provectus Biopharmaceuticals, Inc. 2014 Equity Compensation Plan provides for the issuance of up to 20,000,000 shares of common stock pursuant to stock options for the benefit of eligible employees and directors of the Company. Options granted under the 2014 Equity Compensation Plan are either “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code or options which are not incentive stock options. The stock options are exercisable over a period determined by the Board of Directors (through its Compensation Committee), but generally no longer than 10 years after the date they are granted. As of December 31, 2019, there were 18,900,000 shares available for issuance under the 2014 Equity Compensation Plan. There were no stock options granted during the years ended December 31, 2019 or 2018. The following table summarizes option activity during the year ended December 31, 2019 and 2018: Weighted Average Options Exercise Price Outstanding and exercisable at January 1, 2018 3,350,000 $ 0.90 Granted - - Exercised - - Forfeited (150,000 ) 0.89 Outstanding and exercisable at December 31, 2018 3,200,000 $ 0.89 Granted - - Exercised - - Forfeited (200,000 ) 0.88 Outstanding and exercisable at December 31, 2019 3,000,000 $ 0.88 The following table summarizes information about stock options outstanding at December 31, 2019. Number Outstanding Weighted Average Number Exercisable Exercise Price at December 31, 2019 Life at December 31, 2019 $ 0.67 200,000 3.60 200,000 $ 0.75 950,000 4.11 950,000 $ 0.84 150,000 2.50 150,000 $ 0.88 150,000 4.60 150,000 $ 0.93 575,000 1.76 575,000 $ 0.99 50,000 1.50 50,000 $ 1.00 525,000 0.60 525,000 $ 1.04 200,000 1.50 200,000 $ 1.16 200,000 .50 200,000 3,000,000 2.50 3,000,000 As of December 31, 2019, there was no intrinsic value of outstanding and exercisable options. Warrants During the year-ended December 31, 2018, holders of warrants exercised warrants to purchase 12,653,077 shares of common stock at a price of $0.053 per share. In connection with the exercises, the Company received cash proceeds of $674,409 and issued 12,653,077 shares of common stock. During the year ended December 31, 2019, holders of warrants exercised warrants to purchase 5,045,857 shares of common stock at a price of $0.053 per share. In connection with the exercises, the Company received cash proceeds of $268,943 and issued 5,045,857 shares of common stock. During the year ended December 31, 2019, the Company issued 387,500 five-year immediately vested warrants to a consultant to purchase an aggregate of 387,500 shares of common stock with exercise prices ranging from $1.00 to $2.00 per share. The warrants had an aggregate grant date fair value of $10,113, which was recognized immediately within stock compensation in general and administrative expenses. During the year ended December 31, 2019, the Company issued 37,500 three-year immediately vested warrants to a consultant to purchase an aggregate of 37,500 shares of common stock with an exercise price of $0.2862 per share. The warrants had an aggregate grant date fair value of $1,328, which was recognized immediately within stock compensation in general and administrative expenses. In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Years Ended December 31, 2019 2018 Contractual terms (years) 3.00-5.00 N/A Expected volatility 129%-131 % N/A Risk-free interest rate 1.82%-2.23 % N/A Expected dividend 0.00 % n/a The following table summarizes warrant activity during the year ended December 31, 2019 and 2018: Weighted Average Warrants Exercise Price Outstanding and exercisable at January 1, 2018 186,873,032 $ 0.43 Granted - - Exercised (12,653,077 ) 0.05 Forfeited (37,395,817 ) 1.00 Outstanding and exercisable at December 31, 2018 136,824,138 $ 0.27 Granted 425,000 0.94 Exercised (5,045,857 ) 0.05 Forfeited (6,093,749 ) 1.20 Outstanding and exercisable at December 31, 2019 126,109,532 $ 0.29 The following table summarizes information about warrants outstanding at December 31, 2019. Number Outstanding Weighted Average Number Exercisable Intrinsic Value at December 31, Remaining Contractual at December 31, at December 31, Exercise Price 2019 Life 2019 2019 $ 0.053 94,631,726 1.67 94,631,726 $ 160,874 $ 0.290 37,500 2.66 37,500 $ - $ 0.85 28,482,344 0.48 28,482,344 $ - $ 1.00 1,529,202 0.88 1,529,202 $ - $ 1.12 366,000 4.39 366,000 $ - $ 1.25 1,059,760 0.29 1,059,760 $ - $ 2.00 3,000 4.39 3,000 $ - 126,109,532 2.11 126,109,532 $ 160,874 Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2019 and 2018 are as follows: Year ended December 31 2019 2018 Domestic $ (6,975,747 ) $ (7,954,841 ) Foreign 53,210 (198,214 ) Net Pre-Tax Loss $ (6,922,537 ) $ (8,153,055 ) The income tax provision (benefit) consists of the following: Year ended December 31 2019 2018 Federal: Current $ - $ - Deferred 21.00 % (1,361,582 ) (1,385,438 ) State and local: Current - - Deferred 5.14 % (332,939 ) (338,773 ) 26.14 % (1,694,521 ) (1,724,211 ) Change in valuation allowance 1,694,521 1,724,211 Income tax provision (benefit) $ - $ - The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate is as follows: Year Ended December 31 2019 2018 Tax benefit at federal statutory rate (21.0 )% (21.0 )% State income taxes, net of federal benefit (5.1 )% (5.1 )% Permanent differences (1.3 )% (1.7 )% Change in valuation allowance 24.5 % 20.8 % Prior year true-up (0.1 )% 5.8 % Expiration of state net operating loss carryforwards 3.1 % 1.2 % Miscellaneous (0.0 )% 0.0 % Effective income tax rate 0.0 % 0.0 % The components of the Company’s deferred income taxes are summarized below: December 31 2019 2018 Deferred Tax Assets: Net operating loss carryforwards $ 41,959,558 $ 41,114,624 Stock-based compensation 2,215,928 2,207,465 Research and development credit carryovers 2,917,857 2,791,710 Contribution carryovers 10,062 10,062 Accrued liabilities 1,041,286 490,467 Gross deferred tax assets 48,144,691 46,614,328 Deferred Tax Liabilities: Intangible assets (59,616 ) (235,013 ) Prepaid expenses (91,084 ) (90,881 ) Other (40,581 ) (29,545 ) Gross deferred tax liabilities (191,281 ) (355,439 ) Valuation allowance (47,953,410 ) (46,258,889 ) Deferred tax asset, net of valuation allowance $ - $ - Change in valuation allowance $ (1,694,521 ) $ (1,724,211 ) A valuation allowance against deferred tax assets is required if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets may not be realized. The Company is in the early stages of development and realization of the deferred tax assets is not considered more likely than not. As a result, the Company has recorded a full valuation allowance for the net deferred tax asset. Since inception of the Company on January 17, 2002, the Company has generated federal, state and Australian tax net operating losses of approximately $162M, $154M, and $73k. Under the Tax Cuts and Jobs Act, net operating loss incurred after December 31, 2017 may be carried forward indefinitely. The tax loss carry-forwards of the Company may be subject to limitation by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces the Company’s ability to utilize net operating loss carry-forwards. The Company has determined that there are no uncertain tax positions as of December 31, 2019 or 2018 The Company files income tax returns in the U.S. federal jurisdiction and the state of Tennessee. The Company intends to permanently reinvest earnings in its foreign subsidiary. To date, the Company’s operations conducted by its Australian subsidiary consist primarily of research and development activities. As of December 31, 2019, there were no accumulated earnings and profits in the Company’s foreign subsidiary. At current tax rates, no additional Federal income taxes (net of available tax credits) would be payable if such earnings were to be repatriated.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments	10. Commitments Leases The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022. Payments range from approximately $7,300 to $7,800 per month. Total expense for operating leases for the year ended December 31, 2019 was $102,378, of which, $68,252 was included within research and development and $34,126 was included within general and administrative expenses on the consolidated statement of operations. Total expense for operating leases for the year ended December 31, 2018 was $88,393, of which, $58,928 was included within research and development and $29,465 was included within general and administrative expenses on the consolidated statement of operations. As of December 31, 2019, the Company had no leases that were classified as a financing lease. As of December 31, 2019, the Company did not have additional operating and financing leases that have not yet commenced.  A summary of the Company’s right-of-use assets and liabilities is as follows: Years End Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 89,574 Right-of-use assets lease obligations recognized upon adoption: Operating leases $ 265,550 Weighted Average Remaining Lease Term Operating leases 2.50 Years Weighted Average Discount Rate Operating leases 8.0 % Future minimum payments under non-cancellable lease as of December 31, 2019 were as follows: For the Years Ending December 31, Amount 2020 $ 90,666 2021 92,471 2022 46,687 Total future minimum lease payments 229,824 Less: amount representing imputed interest (22,743 ) Total $ 207,081 Employment Agreement On March 25, 2019, the Company entered into a one-year employment agreement with its CFO that will be renewed automatically for successive one-year periods, unless the Company or CFO provides a notice of non-renewal at least thirty (30) days prior to the end of the term. In the event that coincident with or following a Change in Control (as defined in the agreement), the CFO’s employment with the Company is terminated or the employment agreement is not extended (a) by action of the CFO coincident with or following a Change in Control including the CFO’s death, disability or retirement, or (b) by action of the Company not For Cause (as defined in the agreement) coincident with or following a Change in Control, the Company shall pay the CFO a severance payment equal to 50% of the base salary in the preceding calendar year, payable over six months, as well as certain other specified benefits. In connection with the employment agreement, the CFO was entitled to 50,000 shares of immediately-vested common stock. (See Note 7 Stockholder’s Deficiency for additional information).

401(K) Profit Sharing Plan

401(K) Profit Sharing Plan	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
401(K) Profit Sharing Plan	11. 401(K) Profit Sharing Plan The Company maintains a retirement plan under Section 401(k) of the Internal Revenue Code, which covers all eligible employees. All employees with U.S. source income are eligible to participate in the plan immediately upon employment. There was no contribution made by the Company in 2019 or 2018.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Litigation	12. Litigation Culpepper Travel Expenses and Related Collection Efforts On December 27, 2016, the then-Board of Directors (the “then-Board”) unanimously voted to terminate then-interim Chief Executive Officer, then-Chief Operating Officer, and former Chief Financial Officer, Peter Culpepper (“Culpepper”), effective immediately, from all positions he held with the Company and each of its subsidiaries, “for cause,” in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”), based on the results of the investigation conducted by the Audit Committee of the then-Board regarding improper expense reimbursements to Culpepper. The Company took the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Stipulated Settlement Agreement and Mutual Release in the Kleba Derivative Lawsuit Settlement (the “Derivative Lawsuit Settlement”) such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper’s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,104,543 as of December 31, 2019 and December 31, 2018, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount. Culpepper disputed that he was terminated “for cause” under the Culpepper Employment Agreement. Pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute on June 28, 2017. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating both Culpepper’s claim for severance against the Company and the Company’s claims against Culpepper for improper expense reimbursements and amounts Culpepper owes the Company under the Derivative Lawsuit Settlement (the “Culpepper Arbitration”). On September 12, 2018, the arbitrator issued his final award in favor of the Company. On October 4, 2018, the Company filed a petition with the Chancery Court for Davidson County, Tennessee to confirm the arbitration award. This court entered an order confirming the arbitrator’s award on January 23, 2019. On February 20, 2019, Culpepper filed a motion to alter or amend this judgment. On March 22, 2019, the Chancery Court upheld the arbitration award in favor of the Company. On April 16, 2019, Culpepper filed a Notice of Appeal with the Tennessee Court of Appeals regarding the judgment confirming the arbitration award and the order denying Culpepper’s motion to alter or amend the judgment (the “Culpepper Appeal”). The Company and Culpepper have submitted their respective Culpepper Appeal briefs. Oral argument of the appeal was held on January 7, 2020. The Company expects a ruling from the court of appeals in the first half of 2020, although there are no assurances of timing. The Bible Harris Smith Lawsuit On January 28, 2019, this matter was resolved pursuant to a settlement between the parties, the terms of which are confidential. The proceeds from the settlement were received and recorded during the year ended December 31, 2019. The RSM Lawsuit The Company and RSM participated in a mediation on February 4, 2019, when the matter was resolved pursuant to a settlement between the parties, the terms of which are confidential. On February 27, 2019, the matter was resolved pursuant to a settlement between the parties, the terms of which are confidential. The proceeds from the settlement were received and recorded during the year ended December 31, 2019.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Convertible Notes Payable Subsequent to December 31, 2019, the Company entered into a 2020 Note with a non-related party accredited investor in the aggregate principal amount of $100,000 in connection with 2 nd Exercise of Warrants In addition, holders of 800,000 warrants to purchase the common stock of the Company at $0.0533 per share, have exercised these warrants. The Company has received proceeds in the aggregate amount of $42,640.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the collectability of receivables, the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2019, and 2018, the Company’s cash equivalent consists of Treasury bills.
Cash Concentrations	Cash Concentrations Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future.
Equipment and Furnishings, net	Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers, leasehold improvements and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.
Long-Lived Assets	Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2019 and 2018.
Patent Costs, net	Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are being amortized over the remaining estimated useful lives of the patents, which is approximately one year. Annual amortization of the patents is expected to approximate $228,000 in 2020.
Related Party Receivables	Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 6 - Receivables.
Research and Development	Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. The adoption of ASC 842 had a material impact on the Company’s consolidated balance sheet but did not have a material impact on the Company’s consolidated statement of operations. The impact of the adoption of ASC Topic 842 on the balance sheet as of January 1, 2019 is as follows: As Reported December 31, 2018 Adoption of ASC 842 Balance January 1, 2019 Operating lease right-of-use asset $ - $ 265,550 $ 265,550 Total assets $ 1,988,224 $ 265,550 $ 2,253,774 Current liabilities $ 4,102,407 $ 58,469 $ 4,160,876 Non-current portion of operating lease liability $ - $ 207,081 $ 207,081 Total liabilities $ 19,405,713 $ 265,550 $ 19,671,263
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2019 or 2018.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2019 2018 Warrants 126,109,532 136,824,138 Options 3,000,000 3,200,000 Convertible preferred stock 65,663 65,663 Total potentially dilutive shares 129,175,195 140,089,801 The potential dilutive effect of the conversion of the Company’s convertible notes payable has been excluded from this table since the Company’s Series D Preferred Stock has yet to be designated by the Board.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2019 and 2018. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, receivables, other current assets, accounts payable, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability. In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.
Foreign Currency Translation	Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($61,380 and $308,915 at December 31, 2019 and $15,049 and $336,031 at December 31, 2018, respectively), and expense accounts are translated at a weighted average exchange rate for the years then ended ($53,210 and $247,947 for the years ended December 31, 2019 and 2018, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive income (“AOCI”), which is a separate component of shareholders’ equity. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denomination transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning December 1, 2019 and subsequent interim periods. The Company is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments —Credit Losses, ASU 2019-05, Financial Instruments —Credit Losses (Topic 326) Targeted Transition Relief, ASU 2016-13, the FASB issued ASU 2019-10 Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) and ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments—Credit Losses. These ASUs do not change the core principle of the guidance in ASU 2016-13. Instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard. These ASUs will have the same effective date and transition requirements as ASU 2016-13. The Company adopted ASU 2016-13 on January 1, 2020 and it did not have a material impact on the consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted ASU effective January 1, 2020 and it did not have a material impact on the consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied on a prospective basis. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Adoption of ASC Topic 842	The impact of the adoption of ASC Topic 842 on the balance sheet as of January 1, 2019 is as follows: As Reported December 31, 2018 Adoption of ASC 842 Balance January 1, 2019 Operating lease right-of-use asset $ - $ 265,550 $ 265,550 Total assets $ 1,988,224 $ 265,550 $ 2,253,774 Current liabilities $ 4,102,407 $ 58,469 $ 4,160,876 Non-current portion of operating lease liability $ - $ 207,081 $ 207,081 Total liabilities $ 19,405,713 $ 265,550 $ 19,671,263
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2019 2018 Warrants 126,109,532 136,824,138 Options 3,000,000 3,200,000 Convertible preferred stock 65,663 65,663 Total potentially dilutive shares 129,175,195 140,089,801

Receivables (Tables)

Receivables (Tables)	12 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Summary of Receivables	The following table summarizes the receivables at December 31, 2019 and 2018: December 31, 2019 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 55,058 $ 55,058 Gross receivable $ 455,500 $ 1,649,043 $ 2,104,543 Reserve for uncollectibility (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 55,058 - - 55,058 Short-term receivable - Tax Credit 55,058 - - 55,058 Short-term receivable - Settlement - - - Short-term receivable - Legal - - - Long-term receivable $ - $ - $ - $ - December 31, 2018 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 5,074 $ 5,074 Gross receivable $ 911,000 $ 1,783,795 $ 2,694,795 Reserve for uncollectibility (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable 455,500 134,752 595,326 Short-term receivable - Tax Credit Short-term receivable - Settlement - 134,752 134,752 Short-term receivable - Legal 455,500 - 455,500 Long-term receivable $ - $ - $ - $ -

Stock Incentive Plan and Warr_2

Stock Incentive Plan and Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Summary of Option Activity	The following table summarizes option activity during the year ended December 31, 2019 and 2018: Weighted Average Options Exercise Price Outstanding and exercisable at January 1, 2018 3,350,000 $ 0.90 Granted - - Exercised - - Forfeited (150,000 ) 0.89 Outstanding and exercisable at December 31, 2018 3,200,000 $ 0.89 Granted - - Exercised - - Forfeited (200,000 ) 0.88 Outstanding and exercisable at December 31, 2019 3,000,000 $ 0.88
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2019. Number Outstanding Weighted Average Number Exercisable Exercise Price at December 31, 2019 Life at December 31, 2019 $ 0.67 200,000 3.60 200,000 $ 0.75 950,000 4.11 950,000 $ 0.84 150,000 2.50 150,000 $ 0.88 150,000 4.60 150,000 $ 0.93 575,000 1.76 575,000 $ 0.99 50,000 1.50 50,000 $ 1.00 525,000 0.60 525,000 $ 1.04 200,000 1.50 200,000 $ 1.16 200,000 .50 200,000 3,000,000 2.50 3,000,000
Schedule of Assumptions of Warrants	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Years Ended December 31, 2019 2018 Contractual terms (years) 3.00-5.00 N/A Expected volatility 129%-131 % N/A Risk-free interest rate 1.82%-2.23 % N/A Expected dividend 0.00 % n/a
Summary of Warrant Activity	The following table summarizes warrant activity during the year ended December 31, 2019 and 2018: Weighted Average Warrants Exercise Price Outstanding and exercisable at January 1, 2018 186,873,032 $ 0.43 Granted - - Exercised (12,653,077 ) 0.05 Forfeited (37,395,817 ) 1.00 Outstanding and exercisable at December 31, 2018 136,824,138 $ 0.27 Granted 425,000 0.94 Exercised (5,045,857 ) 0.05 Forfeited (6,093,749 ) 1.20 Outstanding and exercisable at December 31, 2019 126,109,532 $ 0.29
Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding at December 31, 2019. Number Outstanding Weighted Average Number Exercisable Intrinsic Value at December 31, Remaining Contractual at December 31, at December 31, Exercise Price 2019 Life 2019 2019 $ 0.053 94,631,726 1.67 94,631,726 $ 160,874 $ 0.290 37,500 2.66 37,500 $ - $ 0.85 28,482,344 0.48 28,482,344 $ - $ 1.00 1,529,202 0.88 1,529,202 $ - $ 1.12 366,000 4.39 366,000 $ - $ 1.25 1,059,760 0.29 1,059,760 $ - $ 2.00 3,000 4.39 3,000 $ - 126,109,532 2.11 126,109,532 $ 160,874

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Domestic and Foreign Loss Before Income Taxes	The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2019 and 2018 are as follows: Year ended December 31 2019 2018 Domestic $ (6,975,747 ) $ (7,954,841 ) Foreign 53,210 (198,214 ) Net Pre-Tax Loss $ (6,922,537 ) $ (8,153,055 )
Summary of Income Tax Provision (Benefit)	The income tax provision (benefit) consists of the following: Year ended December 31 2019 2018 Federal: Current $ - $ - Deferred 21.00 % (1,361,582 ) (1,385,438 ) State and local: Current - - Deferred 5.14 % (332,939 ) (338,773 ) 26.14 % (1,694,521 ) (1,724,211 ) Change in valuation allowance 1,694,521 1,724,211 Income tax provision (benefit) $ - $ -
Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate	The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate is as follows: Year Ended December 31 2019 2018 Tax benefit at federal statutory rate (21.0 )% (21.0 )% State income taxes, net of federal benefit (5.1 )% (5.1 )% Permanent differences (1.3 )% (1.7 )% Change in valuation allowance 24.5 % 20.8 % Prior year true-up (0.1 )% 5.8 % Expiration of state net operating loss carryforwards 3.1 % 1.2 % Miscellaneous (0.0 )% 0.0 % Effective income tax rate 0.0 % 0.0 %
Schedule of Components of Deferred Income Taxes	The components of the Company’s deferred income taxes are summarized below: December 31 2019 2018 Deferred Tax Assets: Net operating loss carryforwards $ 41,959,558 $ 41,114,624 Stock-based compensation 2,215,928 2,207,465 Research and development credit carryovers 2,917,857 2,791,710 Contribution carryovers 10,062 10,062 Accrued liabilities 1,041,286 490,467 Gross deferred tax assets 48,144,691 46,614,328 Deferred Tax Liabilities: Intangible assets (59,616 ) (235,013 ) Prepaid expenses (91,084 ) (90,881 ) Other (40,581 ) (29,545 ) Gross deferred tax liabilities (191,281 ) (355,439 ) Valuation allowance (47,953,410 ) (46,258,889 ) Deferred tax asset, net of valuation allowance $ - $ - Change in valuation allowance $ (1,694,521 ) $ (1,724,211 )

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Years End Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 89,574 Right-of-use assets lease obligations recognized upon adoption: Operating leases $ 265,550 Weighted Average Remaining Lease Term Operating leases 2.50 Years Weighted Average Discount Rate Operating leases 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under non-cancellable lease as of December 31, 2019 were as follows: For the Years Ending December 31, Amount 2020 $ 90,666 2021 92,471 2022 46,687 Total future minimum lease payments 229,824 Less: amount representing imputed interest (22,743 ) Total $ 207,081

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	Feb. 29, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash and cash equivalents		$ 590,706	$ 50,986
Warrant to purchase common stock		5,045,857	12,653,077
Exercised price per share		$ 0.053	$ 0.053
Proceeds from exercise of warrants		$ 268,943	$ 674,408
Subsequent Event [Member]
Loans received in connection with financing	$ 50,000
Warrant to purchase common stock	800,000
Exercised price per share	$ 0.0533
Proceeds from exercise of warrants	$ 42,640

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019AUD ($)	Dec. 31, 2018AUD ($)
Summary Of Significant Accounting Policy [Line Items]
Maturity of highly liquid investments	Three months or less
Amount of insurance coverage	$ 250,000
Impairment of long lived assets
Recognized income tax positions measured	50.00%
Income taxes, interest or penalties incurred
Foreign currency translation adjustments	61,380	15,049
Foreign currency translation adjustment of expense at weighted average exchange rate	$ 53,210	$ 247,947
Australian Dollar [Member]
Summary Of Significant Accounting Policy [Line Items]
Foreign currency translation adjustments			$ 308,915	$ 336,031
Patents [Member]
Summary Of Significant Accounting Policy [Line Items]
Remaining lives of the patents	1 year
Amortization of patents, 2020	$ 228,000
Computer Equipment [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	5 years
Leasehold Improvements [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	5 years
Office Equipment [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	5 years
Furniture and Fixtures [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	10 years

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Adoption of ASC Topic 842 (Details) - USD ($)	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Summary Of Significant Accounting Policy [Line Items]
Operating lease right-of-use asset	$ 194,400
Total assets	1,476,904		1,988,224
Current liabilities	3,022,912		4,102,407
Non-current portion of operaing lease liability	130,658
Total liabilities	25,549,016		$ 19,405,713
Restated Adjustment [Member]
Summary Of Significant Accounting Policy [Line Items]
Operating lease right-of-use asset		$ 265,550
Total assets		2,253,774
Current liabilities		4,160,876
Non-current portion of operaing lease liability		207,081
Total liabilities		$ 19,671,263
Adoption of ASC 842 [Member]
Summary Of Significant Accounting Policy [Line Items]
Operating lease right-of-use asset	265,550
Total assets	265,550
Current liabilities	58,469
Non-current portion of operaing lease liability	207,081
Total liabilities	$ 265,550

Significant Accounting Polici_6

Significant Accounting Policies - Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	129,175,195	140,089,801
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	65,663	65,663
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	126,109,532	136,824,138
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,000,000	3,200,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 20, 2019	Feb. 28, 2018	Mar. 23, 2017
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Borrowed outstanding convertible notes payable	$ 500,000
2017 Notes [Member] | Non-Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount	6,335,000	2,606,000
Borrowed outstanding convertible notes payable	13,397,000	7,062,000
Trade debt		150,000
2017 Notes [Member] | Dr. Scott's Kleba Settlement Agreement [Member]
Related Party Transaction [Line Items]
Debt principal amount				$ 250,000
2017 Notes [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount	50,000	1,870,000
Borrowed outstanding convertible notes payable	$ 6,670,000	$ 6,870,000
Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Interest rate	8.00%
Event occurs description	If a Company Event occurs within two (2) years of the date of issuance of the Series D Preferred Stock (the "Date of Issuance"), the holders of Series D Preferred Stock shall receive a preference of four times (4x) their respective investment amount. If a Company Event occurs after the second (2nd) anniversary of the Date of Issuance, the holders of the Series D Preferred Stock shall receive a preference of six times (6x) their respective investment amount.
Voting rights description	On an as-converted basis, the Series D Preferred Stock shall carry the right to ten (10) votes per share.
2017 Financing [Member]
Related Party Transaction [Line Items]
Interest rate	8.00%
Debt principal amount	$ 6,335,000
Borrowed outstanding convertible notes payable	$ 13,397,000
2017 Financing [Member] | First And Final Tranche [Member]
Related Party Transaction [Line Items]
Financing arrangement amount			$ 20,000,000
2017 Financing [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 0.2862
2017 Financing [Member] | Series D Preferred Stock [Member] | Final Tranche [Member]
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 0.2862
2017 Financing [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount					$ 10,000,000
2017 Financing [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount					$ 20,000,000
2020 Financing [Member]
Related Party Transaction [Line Items]
Interest rate	8.00%
Loans received in connection with financing	$ 100,000
Debt principal amount	100,000
Borrowed outstanding convertible notes payable	$ 100,000
2020 Financing [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 2.8620
2020 Financing [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount	$ 20,000,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accrued director fees	$ 792,524	$ 407,524
Directors fees	385,000	333,357
Mr Bruce Horowitz [Member]
Consulting fees	277,200	190,000
Accrued director fees	$ 75,000	$ 56,250

Receivables (Details Narrative)

Receivables (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Receivables [Abstract]
Offset against accrued payroll and other payables	$ 535,361	$ 150,000

Receivables - Summary of Receiv

Receivables - Summary of Receivables (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Tax credit	$ 55,058	$ 5,074
Gross receivable	2,104,543	2,694,795
Reserve for uncollectibility	(2,104,543)	(2,104,543)
Net receivable	55,058	595,326
Short-term receivable	55,058
Long-term receivable
Legal Fees [Member]
Gross receivable	455,500	911,000
Reserve for uncollectibility	(455,500)	(455,500)
Net receivable		455,500
Short-term receivable		455,500
Long-term receivable
Settlement [Member]
Gross receivable	1,649,043	1,783,795
Reserve for uncollectibility	(1,649,043)	(1,649,043)
Net receivable		134,752
Short-term receivable		134,752
Long-term receivable
Provectus Australia [Member]
Tax credit	55,058	5,074
Net receivable	55,058
Short-term receivable	$ 55,058
Long-term receivable

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Aug. 25, 2016
Class of Stock [Line Items]
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Employee and Consultants [Member]
Class of Stock [Line Items]
Number of restricted stock issued	229,090	1,000,000
Number of restricted stock issued, value	$ 11,538	$ 80,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	240,000	240,000
Preferred stock, par value			$ 0.001
Preferred stock, dividend percentage	8.00%
Undesignated Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	24,760,000

Stock Incentive Plan and Warr_3

Stock Incentive Plan and Warrants (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of common stock issued
Options, outstanding, intrinsic value
Options, exercisable, intrinsic value
Warrants to purchase shares of common stock	5,045,857	12,653,077
Warrants exercise price	$ 0.053	$ 0.053
Proceeds from warrant exercise	$ 268,943	$ 674,408
Number of shares of common stock issued	5,045,857	12,653,077
Warrants, outstanding, intrinsic value
Warrants, exercisable, intrinsic value
Consultant [Member] | Five Year Immediately Vested Warrants [Member]
Warrants to purchase shares of common stock	387,500
Aggregate purchase of common stock, shares	387,500
Aggregate fair value of warrants	$ 10,113
Consultant [Member] | Three Year Immediately Vested Warrants [Member]
Warrants to purchase shares of common stock	37,500
Warrants exercise price	$ 0.2862
Aggregate purchase of common stock, shares	37,500
Aggregate fair value of warrants	$ 1,328
Maximum [Member] | Consultant [Member] | Five Year Immediately Vested Warrants [Member]
Warrants exercise price	$ 2
Minimum [Member] | Consultant [Member] | Five Year Immediately Vested Warrants [Member]
Warrants exercise price	$ 1
2014 Equity Compensation Plan [Member]
Number of available for issuance	18,900,000
2014 Equity Compensation Plan [Member] | Maximum [Member]
Number of common stock issued	20,000,000
Period of plan	10 years

Stock Incentive Plan and Warr_4

Stock Incentive Plan and Warrants - Summary of Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding and exercisable, beginning balance	3,200,000	3,350,000
Number of Options, Granted
Number of Options, Exercised
Number of Options, Forfeited	(200,000)	(150,000)
Number of Options Outstanding and exercisable, ending balance	3,000,000	3,200,000
Weighted Average Exercise Price Outstanding and exercisable, beginning balance	$ 0.89	$ 0.90
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited	0.88	0.89
Weighted Average Exercise Price Outstanding and exercisable, ending balance	$ 0.88	$ 0.89

Stock Incentive Plan and Warr_5

Stock Incentive Plan and Warrants - Summary of Stock Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number Outstanding	3,000,000
Weighted Average Remaining Contractual Life	2 years 6 months
Number Exercisable	3,000,000
Range One [Member]
Exercise price | $ / shares	$ 0.67
Number Outstanding	200,000
Weighted Average Remaining Contractual Life	3 years 7 months 6 days
Number Exercisable	200,000
Range Two [Member]
Exercise price | $ / shares	$ 0.75
Number Outstanding	950,000
Weighted Average Remaining Contractual Life	4 years 1 month 9 days
Number Exercisable	950,000
Range Three [Member]
Exercise price | $ / shares	$ 0.84
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	2 years 6 months
Number Exercisable	150,000
Range Four [Member]
Exercise price | $ / shares	$ 0.88
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	4 years 7 months 6 days
Number Exercisable	150,000
Range Five [Member]
Exercise price | $ / shares	$ 0.93
Number Outstanding	575,000
Weighted Average Remaining Contractual Life	1 year 9 months 3 days
Number Exercisable	575,000
Range Six [Member]
Exercise price | $ / shares	$ 0.99
Number Outstanding	50,000
Weighted Average Remaining Contractual Life	1 year 6 months
Number Exercisable	50,000
Range Seven [Member]
Exercise price | $ / shares	$ 1
Number Outstanding	525,000
Weighted Average Remaining Contractual Life	7 months 6 days
Number Exercisable	525,000
Range Eight [Member]
Exercise price | $ / shares	$ 1.04
Number Outstanding	200,000
Weighted Average Remaining Contractual Life	1 year 6 months
Number Exercisable	200,000
Range Nine [Member]
Exercise price | $ / shares	$ 1.16
Number Outstanding	200,000
Weighted Average Remaining Contractual Life	6 months
Number Exercisable	200,000

Stock Incentive Plan and Warr_6

Stock Incentive Plan and Warrants - Schedule of Assumptions of Warrants (Details)	Dec. 31, 2019	Dec. 31, 2018
Warrants, contracual terms (years)		0 years
Expected Volatility [Member]
Warrants outstanding, measurement input		0
Risk Free Interest Rate [Member]
Warrants outstanding, measurement input		0
Expected Dividend Rate [Member]
Warrants outstanding, measurement input	0	0
Minimum [Member]
Warrants, contracual terms (years)	3 years
Minimum [Member] | Expected Volatility [Member]
Warrants outstanding, measurement input	129
Minimum [Member] | Risk Free Interest Rate [Member]
Warrants outstanding, measurement input	1.82
Maximum [Member]
Warrants, contracual terms (years)	5 years
Maximum [Member] | Expected Volatility [Member]
Warrants outstanding, measurement input	131
Maximum [Member] | Risk Free Interest Rate [Member]
Warrants outstanding, measurement input	2.23

Stock Incentive Plan and Warr_7

Stock Incentive Plan and Warrants - Summary of Warrant Activity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Warrants Outstanding and exercisable, beginning balance	136,824,138	186,873,032
Warrants, Granted	425,000
Warrants, Exercised	(5,045,857)	(12,653,077)
Warrants, Forfeited	(6,093,749)	(37,395,817)
Warrants Outstanding and exercisable, ending balance	126,109,532	136,824,138
Weighted Average Exercise Price Outstanding and exercisable, beginning balance	$ 0.27	$ 0.43
Weighted Average Exercise Price, Granted	0.94
Weighted Average Exercise Price, Exercised	0.05	0.05
Weighted Average Exercise Price, Forfeited	1.20	1
Weighted Average Exercise Price Outstanding and exercisable, ending balance	$ 0.29	$ 0.27

Stock Incentive Plan and Warr_8

Stock Incentive Plan and Warrants - Summary of Warrants Outstanding (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Weighted Average Exercise price
Number Outstanding	3,000,000
Number Exercisable	3,000,000
Range One [Member]
Number Outstanding	200,000
Number Exercisable	200,000
Range Two [Member]
Number Outstanding	950,000
Number Exercisable	950,000
Range Three [Member]
Number Outstanding	150,000
Number Exercisable	150,000
Range Four [Member]
Number Outstanding	150,000
Number Exercisable	150,000
Range Five [Member]
Number Outstanding	575,000
Number Exercisable	575,000
Range Six [Member]
Number Outstanding	50,000
Number Exercisable	50,000
Range Seven [Member]
Number Outstanding	525,000
Number Exercisable	525,000
Warrant [Member]
Number Outstanding	126,109,532
Weighted Average Remaining Contractual Life	2 years 1 month 9 days
Number Exercisable	126,109,532
Intrinsic Value	$ 160,874
Warrant [Member] | Range One [Member]
Weighted Average Exercise price	$ 0.053
Number Outstanding	94,631,726
Weighted Average Remaining Contractual Life	1 year 8 months 2 days
Number Exercisable	94,631,726
Intrinsic Value	$ 160,874
Warrant [Member] | Range Two [Member]
Weighted Average Exercise price	$ 0.290
Number Outstanding	37,500
Weighted Average Remaining Contractual Life	2 years 7 months 28 days
Number Exercisable	37,500
Intrinsic Value
Warrant [Member] | Range Three [Member]
Weighted Average Exercise price	$ 0.85
Number Outstanding	28,482,344
Weighted Average Remaining Contractual Life	5 months 23 days
Number Exercisable	28,482,344
Intrinsic Value
Warrant [Member] | Range Four [Member]
Weighted Average Exercise price	$ 1
Number Outstanding	1,529,202
Weighted Average Remaining Contractual Life	10 months 17 days
Number Exercisable	1,529,202
Intrinsic Value
Warrant [Member] | Range Five [Member]
Weighted Average Exercise price	$ 1.12
Number Outstanding	366,000
Weighted Average Remaining Contractual Life	4 years 4 months 20 days
Number Exercisable	366,000
Intrinsic Value
Warrant [Member] | Range Six [Member]
Weighted Average Exercise price	$ 1.25
Number Outstanding	1,059,760
Weighted Average Remaining Contractual Life	3 months 15 days
Number Exercisable	1,059,760
Intrinsic Value
Warrant [Member] | Range Seven [Member]
Weighted Average Exercise price	$ 2
Number Outstanding	3,000
Weighted Average Remaining Contractual Life	4 years 4 months 20 days
Number Exercisable	3,000
Intrinsic Value

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Line Items]
Uncertain tax positions
Foreign [Member]
Income Taxes [Line Items]
Tax net operating losses	162,000,000
State [Member]
Income Taxes [Line Items]
Tax net operating losses	154,000,000
Australian [Member]
Income Taxes [Line Items]
Tax net operating losses	$ 73,000

Income Taxes - Schedule of Dome

Income Taxes - Schedule of Domestic and Foreign Loss Before Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Domestic	$ (6,975,747)	$ (7,954,841)
Foreign	53,210	(198,214)
Net Pre-Tax Loss	$ (6,922,537)	$ (8,153,055)

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal: Current
Federal: Deferred	$ (1,361,582)	$ (1,385,438)
Federal: Deferred tax rate	21.00%	21.00%
State and local: Current
State and local: Deferred	$ (332,939)	$ (338,773)
State and local: Deferred tax rate	5.10%	5.10%
Effective deferred tax rate	26.14%	26.14%
Current income tax expense (benefit)	$ (1,694,521)	$ (1,724,211)
Change in valuation allowance	1,694,521	1,724,211
Income tax provision (benefit)

Income Taxes - Schedule of Stat

Income Taxes - Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	(21.00%)	(21.00%)
State income taxes, net of federal benefit	(5.10%)	(5.10%)
Permanent differences	(1.30%)	(1.70%)
Change in valuation allowance	24.50%	20.80%
Prior year true-up	(0.10%)	5.80%
Expiration of state net operating loss carry forwards	3.10%	1.20%
Miscellaneous	(0.00%)	0.00%
Effective income tax rate	0.00%	0.00%

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 41,959,558	$ 41,114,624
Stock-based compensation	2,215,928	2,207,465
Research and development credit carryovers	2,917,857	2,791,710
Contribution carryovers	10,062	10,062
Accrued liabilities	1,041,286	490,467
Gross deferred tax assets	48,144,691	46,614,328
Intangible assets	(59,616)	(235,013)
Prepaid expenses	(91,084)	(90,881)
Other	(40,581)	(29,545)
Gross deferred tax liabilities	(191,281)	(355,439)
Valuation allowance	(47,953,410)	(46,258,889)
Deferred tax asset, net of valuation allowance
Change in valuation allowance	$ (1,694,521)	$ (1,724,211)

Commitments (Details Narrative)

Commitments (Details Narrative)	Mar. 25, 2019shares	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)
Leases payments, per month		$ 89,574
Lease expense		102,378	$ 88,393
Employment Agreement [Member] | CFO [Member]
Employment agreement, description	Company entered into a one-year employment agreement with its CFO that will be renewed automatically for successive one-year periods, unless the Company or CFO provides a notice of non-renewal at least thirty (30) days prior to the end of the term. In the event that coincident with or following a Change in Control (as defined in the agreement), the CFO's employment with the Company is terminated or the employment agreement is not extended (a) by action of the CFO coincident with or following a Change in Control including the CFO's death, disability or retirement, or (b) by action of the Company not For Cause (as defined in the agreement) coincident with or following a Change in Control, the Company shall pay the CFO a severance payment equal to 50% of the base salary in the preceding calendar year, payable over six months, as well as certain other specified benefits.
Number of shares immediately vested | shares	50,000
Research and Development Expense [Member]
Lease expense		68,252	58,928
General and Administrative Expense [Member]
Lease expense		$ 34,126	$ 29,465
Knoxville, Tennessee [Member]
Area of land | ft²		4,500
Lease term		5 years
Lease expiration date		Jun. 30, 2022
Knoxville, Tennessee [Member] | Minimum [Member]
Leases payments, per month		$ 7,300
Knoxville, Tennessee [Member] | Maximum [Member]
Leases payments, per month		$ 7,800

Commitments - Schedule of Right

Commitments - Schedule of Right-of-use Assets and Liabilities (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases	$ 89,574
Right-of-use assets lease obligations recognized upon adoption: Operating leases	$ 265,550
Weighted Average Remaining Lease Term: Operating leases	2 years 6 months
Weighted Average Discount Rate: Operating leases	8.00%

Commitments - Schedule of Futur

Commitments - Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 90,666
2021	92,471
2022	46,687
Total future minimum lease payments	229,824
Less: amount representing imputed interest	(22,743)
Total	$ 207,081

401(K) Profit Sharing Plan (Det

401(K) Profit Sharing Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Retirement Benefits [Abstract]
Contributions to the 401(K) Profit Sharing Plan

Litigation (Details Narrative)

Litigation (Details Narrative) - Culpepper Employment Agreement [Member] - Peter Culpepper [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Damages sought to be receivable	$ 2,240,000
Litigation cost	227,750
Litigation reserve	$ 2,104,543	$ 2,104,543

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 29, 2020	Feb. 29, 2020	Dec. 31, 2019	Dec. 31, 2018
Warrant to purchase common stock			5,045,857	12,653,077
Exercised price per share			$ 0.053	$ 0.053
Proceeds from exercise of warrants			$ 268,943	$ 674,408
Subsequent Event [Member]
Warrant to purchase common stock	800,000	800,000
Exercised price per share	$ 0.0533	$ 0.0533
Proceeds from exercise of warrants	$ 42,640
Subsequent Event [Member] | 2020 Note [Member] | Non-Related Party [Member]
Debt instrument, face amount	$ 100,000	$ 100,000
Proceeds from related party